Medical Industry Feature: Efficacy of a Next Generation LV Prep

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Efficacy of a Next Generation Low Volume Bowel Prep

Efficacy of a Next Generation Low Volume Bowel Prep

Dr. Hookey will introduce a recently published study of a next generation low volume bowel prep reviewing the efficacy, safety, and tolerability data.

  • Sponsored by

  • Overview

    Dr. Lawrence Hookey joins Dr. Sophie Balzora to discuss the clinical trial of a next generation low volume prep with proven efficacy and an established safety profile and tolerability data.

  • Indication and Important Safety Information


    CLENPIQ is indicated for cleansing of the colon as a preparation for colonoscopy in adults.

    Important Safety Information

    CLENPIQ is contraindicated in the following conditions: patients with severe renal impairment (creatinine clearance less than 30mL/minute), gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, or in patients with a known hypersensitivity to any of the ingredients in CLENPIQ.

    Patients should be advised to hydrate adequately (before, during and after use of CLENPIQ), and post-colonoscopy lab tests should be considered if a patient develops significant vomiting or signs of dehydration, including orthostatic hypotension, after taking CLENPIQ. Patients with electrolyte abnormalities should have them corrected before treatment. Use caution when prescribing CLENPIQ for patients that have conditions or are using medications that increase the risk for fluid and electrolyte abnormalities.

    Use caution in patients who have conditions, or are taking concomitant medications that increase the risk for seizures, such as those taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines or patients with known or suspected hyponatremia.

    Use caution in patients with impaired renal function or taking medications that may affect renal function, as well as patients at increased risk of arrhythmias, including those patients with a history of prolonged QT, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy.

    Osmotic laxatives may produce colonic mucosal aphthous ulcerations and there have been reports of more serious cases of ischemic colitis requiring hospitalization. Concurrent use of additional stimulant laxatives with CLENPIQ may increase this risk.

    Use with caution in patients with severe active ulcerative colitis.

    Use with caution in patients with impaired gag reflex as they may be at risk for regurgitation or aspiration during administration of CLENPIQ.

    The safety of CLENPIQ has been established from adequate well-controlled trials of another oral formulation of sodium picosulfate, magnesium oxide, and anhydrous citric acid. The most common adverse reactions in those trials were nausea, headache, and vomiting.

    CLENPIQ can reduce the absorption of co-administered drugs. Do not take oral medications within one hour of starting CLENPIQ. Administer tetracycline and fluoroquinolone antibiotics, iron, digoxin, chlorpromazine and penicillamine, at least 2 hours before and not less than 6 hours after administration of CLENPIQ to avoid chelation with magnesium.

    You are encouraged to report negative side effects of prescription drugs to FDA. Visit, or call 800.FDA.1088. 

    Please see Full Prescribing Information


LIVE ON REACHMD RADIOBack to live radio


Programs 4/8/20